Application of benzamide compound in prevention and treatment of malignant tumor cachexia

By using the p38 MAPK inhibitor TAK-715, the signaling pathway that inhibits the activation of inflammatory factors is solved, and the skeletal muscle atrophy caused by malignant tumor cachexia is provided, which provides an effective pharmaceutical composition, significantly improves the symptoms of malignant tumor cachexia and broadens the treatment. choose.

CN119015281AActive Publication Date: 2024-11-26INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202310597849.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-25
Publication Date
2024-11-26
Estimated Expiration
2043-05-25

AI Technical Summary

Technical Problem

The prior art lacks effective methods to treat and prevent malignant tumor cachexia, especially skeletal muscle atrophy, resulting in a decline in the quality of life of patients and unsatisfactory treatment results.

Method used

Using a p38 MAPK inhibitor compound TAK-715, it improves skeletal muscle atrophy caused by malignant tumor cachexia by inhibiting the activation of inflammatory factors, and provides pharmaceutical compositions to prevent or treat malignant tumor cachexia, including solutions, suspensions, For dosage forms such as lyophilized powder injections, emulsions, etc., pharmaceutically acceptable carriers such as starch, dextrin, sodium polymethylcellulose, etc. are used.

Benefits of technology

It significantly improves animal weight loss, skeletal muscle atrophy and fat loss caused by malignant tumor cachexia, broadens the selection field for the treatment of nutritional deficiency and consumption syndrome, and provides the first effective medicine in malignant tumor cachexia.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015281A_ABST
    Figure CN119015281A_ABST
Patent Text Reader

Abstract

The invention relates to application of a compound in the field of biomedicine, in particular to application of a benzamide compound in preparation of a medicine for preventing and / or treating malignant tumor cachexia. The compound shown in the formula I or the pharmaceutically acceptable salt of the compound is used for preparing a medicine for preventing and / or treating malignant tumor cachexia. The compound provided by the invention has the effects of remarkably improving and relieving malignant tumor cachexia, improves the weight of animals and the weight of skeletal muscle and fat, and has good application and development prospects. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a method for assisting the treatment of malignant tumors for preventing and / or treating malignant tumor cachexia, and belongs to the field of biomedicine. The method is that when a patient has a malignant tumor, the compound is used to prevent and / or treat cachexia and assist the treatment of the malignant tumor. Background Art

[0002] Cancer is one of the leading causes of death worldwide. The World Health Organization reported in 2020 that nearly 10 million people die from cancer each year, and nearly one-sixth of the world's population deaths are caused by cancer. Cancer is characterized by the rapid generation of abnormal cells, which can invade nearby sites and spread to other organs.

[0003] Malignant tumor cachexia is a group of wasting syndromes characterized by muscle tissue, fat loss and progressive malnutrition, manifested as progressive weight loss, fatigue, loss of appetite, and varying degrees of damage to organs throughout the body, leading to a decline in quality of life and increased mortality. The most important feature of cachexia is muscle loss with or without a decrease in fat mass. Cachexia is different from starvation and age-related muscle loss. Although cachexia usually occurs in the late stages of malignant tumors, 60%-80% of malignant tumor patients may develop cachexia at any stage of the tumor, seriously affecting the body's sensitivity and tolerance to treatment. About 20% of malignant tumor patients die from cachexia. Patients in a cachectic state receive various anti-tumor treatments, which cannot exert the anti-tumor therapeutic effect, but increase complications and toxic side effects. Malignant tumor cachexia is a clinical syndrome that can be prevented and treated in advance.

[0004] The mechanism of cachexia in malignant tumors is still unclear. Currently, it is mainly believed that it is the accelerated loss of skeletal muscle under inflammatory response. Cytokine activation and several factors that originate from tumors and potentially induce cachexia may play an important role. A variety of inflammatory factors can lead to hypermetabolism, such as TNF-α, IL-1β and IL-6. In tumor patients with weight loss, there is also an increase in the number of inflammatory factors and skeletal muscle atrophy. Skeletal muscle atrophy is manifested as a decrease in skeletal muscle mass and strength. It can not only increase the mortality rate of patients with malignant tumors, but also affect the quality of life of patients. However, there is currently a lack of effective treatment for malignant tumor cachexia, especially skeletal muscle atrophy. Existing methods include increasing the intake of various nutrients, especially proteins rich in essential amino acids, to offset high catabolism and promote food intake. For situations where nutritional treatment is not ideal, drug treatment can be used, including drugs that promote appetite, drugs that promote gastric motility, steroid hormones, and non-steroidal anti-inflammatory drugs. However, at present, the treatment results of the above drugs are still unsatisfactory.

[0005] The compound Tak-715 described in the present invention is a p38 MAPK inhibitor. MAPK family proteins are evolutionarily conserved serine / threonine protein kinases that play a core role in signal transduction pathways. p38MAPK can be activated by many extracellular and intracellular stimuli, including proinflammatory factors, reactive oxygen species, and stressors. Based on bioinformatics, in vivo and in vitro screening and verification, we found that the small molecule p38 MAPK inhibitor TAK-715 has a good effect on improving skeletal muscle atrophy caused by malignant tumor cachexia. Our research found that Tak-715 has an improving effect on the cachexia state of C57BL / 6J mice induced by inflammation and Lewis lung cancer. The use of Tak-715 in the treatment or prevention of malignant tumor cachexia in the present invention is disclosed for the first time. Summary of the invention

[0006] The technical problem to be solved by the present invention is to provide an application of a compound in the treatment and prevention of cachexia of malignant tumors.

[0007] In order to solve the technical problem of the present invention, the present invention provides the following technical solutions:

[0008] The first aspect of the technical solution of the present invention is to provide the use of a compound as shown in formula (I) and a pharmaceutically acceptable salt thereof in the preparation of a drug for preventing or treating cachexia of a malignant tumor.

[0009]

[0010] CAS No.: 303162-79-0(Ⅰ).

[0011] The malignant tumor cachexia is selected from malignant epithelial tumors, malignant mesenchymal tumors, leukemia, lymphoma, and myeloma.

[0012] A mouse cachexia model induced by inflammatory factors and malignant tumor cells was used to detect the effects of the compound on the body weight, skeletal muscle and adipose tissue of the animals and to determine the application of the compound in the preparation of a drug for preventing and / or treating malignant tumor cachexia.

[0013] The object of the present invention is to provide a compound as shown in the general formula: (I) and its pharmaceutically acceptable salt for use in the preparation of a drug for preventing or treating malignant tumor cachexia.

[0014] The compound represented by general formula (I) has the molecular formula C 24 H 21 N 3OS, chemical name N-[4-[2-ethyl-4-(3-methylphenyl)-5-thiazolyl]-2-pyridyl]benzamide, CAS number 303162-79-0, is a p38MAPK inhibitor. Currently, there are no reports or patents on Tak-715 in improving cachexia of malignant tumors in the world.

[0015] The second aspect of the technical solution of the present invention is to provide a pharmaceutical composition for use in the preparation of a drug for treating and / or preventing malignant tumor cachexia, characterized in that the pharmaceutical composition contains an effective dose of the compound as shown in (I) and a pharmaceutically acceptable salt thereof,

[0016]

[0017] CAS No.: 303162-79-0(Ⅰ).

[0018] The pharmaceutical composition includes the following dosage forms: solution, suspension, freeze-dried powder injection, emulsion, pill, capsule, powder, controlled release, sustained release preparation and microsome delivery system.

[0019] The pharmaceutically acceptable carriers include starch, dextrin, polymethylcellulose sodium, magnesium stearate and talc.

[0020] The present invention relates to a pharmaceutical composition represented by general formula (I), comprising an effective amount of a compound represented by general formula (I) and a pharmaceutically acceptable salt. The pharmaceutical composition can be prepared according to methods known in the art. Any dosage form suitable for human or animal use can be prepared by combining the compound of the present invention with one or more pharmaceutically acceptable solid or liquid excipients and / or adjuvants. The content of the compound of the present invention in its pharmaceutical composition is usually 0.1-99.9% by weight.

[0021] The dosage of the pharmaceutical composition of the compound of the present invention can vary widely according to the nature and severity of the disease to be prevented or treated, the individual conditions of the patient or animal, the route of administration and the dosage form. Generally speaking, the suitable daily dosage range of the compound of the present invention is 0.01-1000 mg / kg body weight, preferably 0.1-100 mg / kg body weight. The above dosage can be administered in one dosage unit or divided into several dosage units, depending on the clinical experience of the doctor and the dosage regimen including the use of other treatment means. The compound or composition of the present invention can be used alone or in combination with other therapeutic drugs or symptomatic drugs. When the compound of the present invention has a synergistic effect with other therapeutic drugs, its dosage should be adjusted according to the actual situation.

[0022] The compound of the present invention or the pharmaceutical composition containing the same can be administered in a unit dosage form, and the administration route is parenteral, such as intravenous injection, intramuscular injection, subcutaneous injection, nasal cavity, oral mucosa, eyes, lungs and respiratory tract, skin, rectum, etc. The dosage form is a liquid dosage form. The liquid dosage form can be a solution (including true solution and colloidal solution), emulsion (including o / w type, w / o type and multiple emulsion), suspension, injection (including water injection, powder injection and infusion), eye drops, nasal drops, lotion and liniment, etc.; the compound of the present invention can be made into a common preparation, or it can be made into a sustained-release preparation, a controlled-release preparation, a targeted preparation and various microparticle delivery systems.

[0023] Beneficial technical effects

[0024] 1. The compounds of the present invention can prevent and / or treat cachexia of malignant tumors. The use of the compounds of the present invention in preventing and / or treating cachexia of malignant tumors is disclosed for the first time. In particular, there is no clinically effective drug for such diseases. The compounds broaden the selection of drugs for treating nutritional deficiency and wasting syndrome.

[0025] 2. Currently, there are no patents or literature reports on TAK-715 in the treatment of malignant tumor cachexia. This patent is the first to report that the compound has the effect of resisting nutritional deficiency and wasting syndrome.

[0026] 3. The application of the compounds of the present invention has been shown to significantly improve the weight loss, skeletal muscle atrophy and fat loss of animals caused by malignant tumor cachexia. It has obvious benefits to be developed as a drug. DETAILED DESCRIPTION

[0027] The following further illustrates the role of the compound represented by general formula (I) in the preparation of drugs for preventing, alleviating and / or treating cachexia of malignant tumors in conjunction with the present invention.

[0028] The following examples illustrate the present invention in more detail, but are not intended to limit the present invention in any way. Therefore, non-essential improvements and adjustments made to the embodiments by those skilled in the art based on the above-mentioned invention contents still fall within the scope of protection of the present invention.

[0029] Example 1. Preparation of compounds

[0030] The compound TAK-715 was purchased from Selleck (Cat. No. S2928) with a purity of >99.97%. The compound powder was dissolved in DMSO to prepare a 100 mg / mL solution, which was then divided and stored at -80°C for later use. It was diluted with physiological saline to the corresponding concentration when used.

[0031] Example 2. Effects of compounds on LPS-induced body weight in C57BL / 6J mice

[0032] Significance: Cachexia of malignant tumors is closely related to systemic inflammation levels. This experiment observed the effect of lipopolysaccharide (LPS) on animal body weight to reflect the effect of drugs on systemic consumption induced by inflammatory factors.

[0033] Experimental methods: After one week of adaptive feeding, SPF male C57BL / 6 mice were randomly divided into three groups, with 10 mice in each group: normal control group (NC group), LPS group (1 mg / kg), and LPS (1 mg / kg) + TAK-715 (10 mg / kg) group. TAK-715 was orally administered at 10 mg / kg per day, and after 3 days, LPS was intraperitoneally injected at a dose of 0.1 mL / 10 g, and then TAK-715 was continued for 3 weeks.

[0034] Experimental results: In this experiment, the model group animals lost weight, and TAK-715 administration had no significant effect on body weight (Table 1). After LPS was administered to mice, running caused a sudden decrease in body weight, and TAK-715 could significantly improve this phenomenon (Table 2).

[0035] Table 1 Effects of compounds on LPS-induced body weight changes in C57BL / 6J mice

[0036]

[0037] Table 2 Effects of compounds on body weight changes of C57BL / 6J mice after exercise induced by LPS

[0038]

[0039] Example 3. Effects of compounds on LPS-induced tensile strength in mice

[0040] Significance: Skeletal muscle strength is the main indicator of skeletal muscle contraction function and is closely related to the degree of skeletal muscle atrophy. Skeletal muscle tensile test reflects the maximum strength of animal skeletal muscle.

[0041] Experimental method: After one week of adaptive feeding, SPF male C57BL / 6 mice were randomly divided into three groups, with 10 mice in each group: normal control group (NC group), LPS group (1 mg / kg), and LPS (1 mg / kg) + TAK-715 (10 mg / kg) group. TAK-715 was orally administered at 10 mg / kg per day. After 3 days, LPS was intraperitoneally injected at a dose of 0.1 mL / 10 g, and then TAK-715 was continued for 3 weeks. After 2 weeks of administration, the mouse forelimb pulling force was tested using a mouse muscle grip meter. The forelimb pulling force of each animal was tested 10 times, and the maximum value was selected as the value of this animal.

[0042] Experimental results: In this experiment, the forelimb pulling force of the model group was significantly lower than that of the control group, while TAK-715 could significantly increase the muscle pulling force of the forelimbs of LPS-induced mice, indicating that TAK-715 has the effect of improving muscle strength. The results are shown in Table 3.

[0043] Table 3 Effects of compounds on LPS-induced forelimb pulling force in mice

[0044]

[0045]

[0046] Example 4. Effect of the compound on the body weight of C57BL / 6J mice induced by Lewis lung adenocarcinoma cells

[0047] Significance: The highest incidence of cachexia is seen in lung cancer, pancreatic cancer, esophageal cancer, gastrointestinal cancer, and head and neck cancer. Lewis lung adenocarcinoma (LLC) cells are commonly used to induce cachexia in mice. This tumor induces rapid and progressive body and tissue wasting. This experiment observed the effects of drugs on body weight in the Lewis lung adenocarcinoma cell-induced cachexia model to reflect the effects of drugs on tumor-induced systemic wasting.

[0048] Experimental methods: Male mice (C57BL / 6) aged 4-6 weeks were divided into two groups, control group and model group. For LLC-induced cancer cachexia model, 100 μL LLC cells (5×10 6 ) or an equal amount of normal saline (normal control). On the 5th day after LLC implantation, the mice were weighed and the volume of subcutaneous tumors was measured. According to body weight and tumor volume, the mice were divided into model group (LLC group) and model + drug administration group (LLC + 3mg / kg TAK-715 group). The drug was intraperitoneally injected at a dose of 0.1mL / 10g. The specific dosing schedule is as follows: 1) NC group: intraperitoneal injection of normal saline; 2) LLC group: intraperitoneal injection of normal saline; 3) LLC + 3mg / kg TAK-715 group: intraperitoneal injection of 3mg / kg TAK-715 for 18 days. The mice were dosed daily, and the development of cachexia was monitored by tumor size, body weight and pulling force.

[0049] Experimental results: In this experiment, the body weight of the animals in the model group decreased; after administration of TAK-715, the body weight level increased, indicating that TAK-715 can improve the weight loss of animals induced by LLC. The results are shown in Table 4.

[0050] Table 4 Effects of compounds on body weight of C57BL / 6J mice induced by Lewis lung adenocarcinoma cells

[0051]

[0052] Example 5. Effects of compounds on skeletal muscle weight of C57BL / 6J mice induced by Lewis lung adenocarcinoma cells

[0053] Significance: The highest incidence of cachexia is seen in lung cancer, pancreatic cancer, esophageal cancer, gastrointestinal cancer, and head and neck cancer. Lewis lung adenocarcinoma (LLC) cells are commonly used to induce cachexia in mice. This tumor induces rapid and progressive body and tissue wasting. This experiment observed the effects of drugs on skeletal muscle weight in the Lewis lung adenocarcinoma cell-induced cachexia model to reflect the effects of drugs on tumor-induced skeletal muscle wasting.

[0054] Experimental methods: Male mice (C57BL / 6) aged 4-6 weeks were divided into two groups, control group and model group. For LLC-induced cancer cachexia model, 100 μL LLC cells (5×10 6 ) or an equal amount of normal saline (normal control). On the 5th day after LLC implantation, the mice were weighed and the volume of subcutaneous tumors was measured. According to body weight and tumor volume, the mice were divided into model group (LLC group) and model + drug administration group (LLC + 3mg / kg TAK-715 group). The drug was administered by intraperitoneal injection at a dose of 0.1mL / 10g. The specific dosing schedule is as follows: 1) NC group: intraperitoneal injection of normal saline; 2) LLC group: intraperitoneal injection of normal saline; 3) LLC + 3mg / kg TAK-715 group: intraperitoneal injection of 3mg / kg TAK-715 for 18 days. The mice were dosed daily, and the development of cachexia was monitored by tumor size, body weight and tension. After the last dose, the skeletal muscle weight of the mice was measured.

[0055] Experimental results: In this experiment, the skeletal muscle weight of the animals in the model group decreased; after TAK-715 administration, the gastrocnemius muscle weight level increased, indicating that TAK-715 can improve the LLC-induced decrease in animal skeletal muscle weight. The results are shown in Table 5.

[0056] Table 5 Effects of compounds on skeletal muscle weight of C57BL / 6J mice induced by Lewis lung adenocarcinoma cells

[0057]

[0058] Example 6. Effects of compounds on skeletal muscle tension in C57BL / 6J mice induced by Lewis lung adenocarcinoma cells

[0059] Significance: The incidence of cachexia is highest in lung cancer, pancreatic cancer, esophageal cancer, gastrointestinal cancer, and head and neck cancer. The cachexia model in mice is often induced by Lewis lung adenocarcinoma cells (LLC). This tumor induces rapid and progressive body and tissue wasting. This experiment observed the effect of drugs on skeletal muscle tension in the cachexia model induced by Lewis lung adenocarcinoma cells to reflect the effect of drugs on tumor-induced skeletal muscle wasting. Skeletal muscle strength is the main indicator of skeletal muscle contractile function and is closely related to the degree of skeletal muscle atrophy. Skeletal muscle tension test reflects the maximum strength of animal skeletal muscle.

[0060] Experimental methods: Male mice (C57BL / 6) aged 4-6 weeks were divided into two groups, control group and model group. For LLC-induced cancer cachexia model, 100 μL LLC cells (5×10 6 ) or an equal amount of normal saline (normal control). On the 5th day after LLC implantation, the mice were weighed and the volume of subcutaneous tumors was measured. According to the body weight and tumor volume, the mice were divided into model group (LLC group) and model + drug administration group (LLC + 3mg / kg TAK-715 group). The drug was administered by intraperitoneal injection at a dose of 0.1mL / 10g. The specific dosing schedule is as follows: 1) NC group: intraperitoneal injection of normal saline; 2) LLC group: intraperitoneal injection of normal saline; 3) LLC + 3mg / kg TAK-715 group: intraperitoneal injection of 3mg / kg TAK-715 for 18 days. The mice were dosed daily, and the development of cachexia was monitored by tumor size, body weight and tension. The forelimb tension of mice was tested using a mouse muscle grip strength meter. The forelimb tension of each animal was tested 10 times, and the maximum value was selected as the value of this animal.

[0061] Experimental results: In this experiment, the explosive force of the pulling force of the animals in the model group was reduced; after 2 weeks of TAK-715 administration, the explosive force level of the forelimbs increased, indicating that TAK-715 can improve the LLC-induced reduction in the pulling force of animal skeletal muscles. The results are shown in Table 6.

[0062] Table 6 Effects of compounds on the tensile strength of C57BL / 6J mice induced by Lewis lung adenocarcinoma cells

[0063]

[0064] Example 7. Effect of Compounds on Fat Weight of C57BL / 6J Mice Induced by Lewis Lung Adenocarcinoma Cells

[0065] Significance: The highest incidence of cachexia is seen in lung cancer, pancreatic cancer, esophageal cancer, gastrointestinal cancer, and head and neck cancer. Lewis lung adenocarcinoma (LLC) cells are commonly used to induce cachexia in mice. This tumor induces rapid and progressive body and tissue wasting. This experiment observed the effects of drugs on fat weight in Lewis lung adenocarcinoma cell-induced cachexia models to reflect the effects of drugs on tumor-induced energy and fat consumption.

[0066] Experimental methods: Male mice (C57BL / 6) aged 4-6 weeks were divided into two groups, control group and model group. For LLC-induced cancer cachexia model, 100 μL LLC cells (5×10 6 ) or an equal amount of normal saline (normal control). On the 5th day after LLC implantation, the mice were weighed and the volume of subcutaneous tumors was measured. According to body weight and tumor volume, the mice were divided into model group (LLC group) and model + drug administration group (LLC + 3mg / kg TAK-715 group). The drug was administered by intraperitoneal injection at a dose of 0.1mL / 10g. The specific dosing schedule is as follows: 1) NC group: intraperitoneal injection of normal saline; 2) LLC group: intraperitoneal injection of normal saline; 3) LLC + 3mg / kg TAK-715 group: intraperitoneal injection of 3mg / kg TAK-715 for 18 days. The mice were dosed daily, and the development of cachexia was monitored by tumor size, body weight and tension. After the last dose, the fat weight of the mice was measured.

[0067] Experimental results: In this experiment, the fat weight of the animals in the model group decreased; after TAK-715 administration, the decrease in adipose tissue weight of the mice was improved, indicating that TAK-715 can improve the LLC-induced decrease in animal fat weight. The results are shown in Table 7.

[0068] Table 7 Effects of compounds on fat weight of C57BL / 6J mice induced by Lewis lung adenocarcinoma cells

[0069]

Claims

1. Use of the compound represented by formula (I) and its pharmaceutically acceptable salt in the preparation of a drug for preventing or treating cachexia of malignant tumors, 2. The use according to claim 1, characterized in that The medicine can maintain the body weight of patients with malignant tumors.

3. The use according to claim 1, characterized in that The drug can maintain skeletal muscle mass and strength in patients with malignant tumors.

4. The use according to any one of claims 1 to 3, characterized in that The malignant tumor is selected from malignant epithelial tumor, malignant mesenchymal tumor, leukemia, lymphoma and myeloma.

5. Use of a pharmaceutical composition in the preparation of a drug for preventing, alleviating and / or treating cachexia of a malignant tumor, characterized in that: The pharmaceutical composition contains an effective dose of the compound as described in (1) and a pharmaceutically acceptable salt thereof; 6. Use according to claim 5, characterized in that The pharmaceutical composition includes the following dosage forms: solution, suspension, freeze-dried powder injection, emulsion, pill, capsule, powder, controlled release, sustained release preparation and microsome delivery system.

7. The use according to claim 5, characterized in that The pharmaceutically acceptable carriers include starch, dextrin, polymethylcellulose sodium, magnesium stearate and talc.

Citation Information

Patent Citations

  • 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof

    CN1353710A

  • Concomitant drugs

    EP1354603A1

  • Concomitant drugs

    WO2002051442A1